Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18

Clinical and Experimental Immunology

Volumn 181, Issue 2, 2015, Pages 219-229

  Ciccia, F ^a   Guggino, G ^a,b   Rizzo, A ^c   Bombardieri, M ^d   Raimondo, S ^b   Carubbi, F ^e   Cannizzaro, A ^c   Sireci, G ^b   Dieli, F ^b   Campisi, G ^b   Giacomelli, R ^e   Cipriani, Paola ^e   De Leo, G ^b   Alessandro, R ^b   Triolo, G ^a  

^a Dipartimento Biomedico di Medicina Interna e Specialistiche   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

IL 18; IL 22; IL 22BP; IL 22R1; Non Hodgkin lymphoma; Sj gren's syndrome

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR 1; UNCLASSIFIED DRUG; IL22RA2 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-22; INTERLEUKIN-22 RECEPTOR; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INFLAMMATORY INFILTRATE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SJOEGREN SYNDROME; TH17 CELL; AGED; BONE MARROW CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LACRIMAL APPARATUS; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PRIMARY CELL CULTURE; SALIVARY GLAND; SIALOADENITIS; SIGNAL TRANSDUCTION;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-18; INTERLEUKINS; LACRIMAL APPARATUS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, NON-HODGKIN; MACROPHAGES; MALE; MIDDLE AGED; MYELOID CELLS; PRIMARY CELL CULTURE; RECEPTORS, INTERLEUKIN; SALIVARY GLANDS; SIALADENITIS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; STAT3 TRANSCRIPTION FACTOR;

EID: 84948070672     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12643     Document Type: Article

References (26)

1. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010; 69:945-8.
2. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 2011; 7:360-8.
3. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2014; 73:1151-6.
4. Bombardieri M, Barone F, Pittoni V et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004; 6:R447-56.
5. Ciccia F, Guggino G, Rizzo A et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012; 71:295-301.
6. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013; 252:116-32.
7. Lin C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014; 25:257-71.
8. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013; 4:289.
9. Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 2004; 4:669-77.
10. Huber S, Gagliani N, Zenewicz LA et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491:259-63.
11. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-8.
12. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974; 37:217-29.
13. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008; 22:1595-603.
14. Gelebart P, Zak Z, Dien-Bard J, Anand M, Lai R. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011; 4:9-19.
15. Ding BB, Yu JJ, Yu RY et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111:1515-23.
16. Lavoie TN, Stewart CM, Berg KM, Li Y, Nguyen CQ. Expression of interleukin-22 in Sjögren's syndrome: significant correlation with disease parameters. Scand J Immunol 2011; 74:377-82.
17. Baldini C, Rossi C, Ferro F et al. The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome. J Intern Med 2013; 274:480-9.
18. Chleq-Deschamps CM, LeBrun DP, Huie P et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993; 81:293-8.
19. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010; 34:400-7.
20. Khader SA, Guglani L, Rangel-Moreno J et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 2011; 187:5402-7.
21. Savan R, McFarland AP, Reynolds DA et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011; 117:575-84.
22. Ye ZJ, Zhou Q, Yin W et al. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett 2012; 326:23-32.
23. Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol 2012; 168:192-9.
24. Miyagaki T, Sugaya M, Suga H et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 2011; 17:7529-38.
25. Jiang R, Tan Z, Deng L et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54:900-9.
26. Manoussakis MN, Boiu S, Korkolopoulou P et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007; 56:3977-88.